Bill Text: TX SB403 | 2023-2024 | 88th Legislature | Comm Sub
Bill Title: Relating to a study on the adverse reactions and efficacy of COVID-19 vaccines.
Spectrum: Partisan Bill (Republican 17-0)
Status: (Engrossed - Dead) 2023-05-23 - Committee report sent to Calendars [SB403 Detail]
Download: Texas-2023-SB403-Comm_Sub.html
| By: Springer, et al. | S.B. No. 403 | |
| (Capriglione, et al.) | ||
|
|
||
|
|
||
| relating to a study on the adverse reactions and efficacy of | ||
| COVID-19 vaccines. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. DEFINITIONS. In this Act: | ||
| (1) "Center" means The University of Texas Health | ||
| Science Center at Houston. | ||
| (2) "COVID-19" means the disease associated with | ||
| exposure from: | ||
| (A) the SARS-CoV-2 virus, including any variants | ||
| of the virus; or | ||
| (B) a COVID-19 vaccine injection. | ||
| (3) "Department" means the Department of State Health | ||
| Services. | ||
| (4) "Vaccine" means a substance used to stimulate | ||
| immunity to a particular infectious disease or pathogen. | ||
| SECTION 2. STUDY. (a) The department, in collaboration | ||
| with the center, shall conduct a study to assess the full scope of | ||
| adverse reactions, including death, and efficacy of COVID-19 | ||
| vaccines used in this state. | ||
| (b) In conducting the study, the department shall compile | ||
| information regarding: | ||
| (1) the immediate short-term side effects and adverse | ||
| reactions experienced by vaccine recipients, including: | ||
| (A) pain, swelling, or redness at the vaccine | ||
| injection site; | ||
| (B) mild fever; | ||
| (C) chills; | ||
| (D) tiredness; | ||
| (E) headache; and | ||
| (F) muscle or joint aches; | ||
| (2) the immediate serious side effects and adverse | ||
| reactions experienced by vaccine recipients, including: | ||
| (A) difficulty breathing; | ||
| (B) swelling of the face or throat; | ||
| (C) accelerated heartbeat; | ||
| (D) body rash; | ||
| (E) dizziness; and | ||
| (F) weakness; | ||
| (3) the long-term side effects and adverse reactions | ||
| experienced by vaccine recipients, including: | ||
| (A) paralysis; | ||
| (B) myocarditis; | ||
| (C) clotting disorders; | ||
| (D) thrombosis with thrombocytopenia syndrome; | ||
| (E) Guillain-Barré syndrome; | ||
| (F) difficulty thinking or brain fog; | ||
| (G) chronic pain; | ||
| (H) tiredness or fatigue; | ||
| (I) loss of taste; | ||
| (J) depression; | ||
| (K) anxiety; and | ||
| (L) death; and | ||
| (4) any misrepresentation or concealment regarding | ||
| the efficacy or dangers of vaccination by the vaccine manufacturer | ||
| or a governmental agency. | ||
| (c) In conducting the study, the department and the center | ||
| shall compile and make available information described by | ||
| Subsection (b) of this section, including information collected by: | ||
| (1) the department, including information collected | ||
| by the department's vital statistics unit, and center; | ||
| (2) hospitals or treatment centers; | ||
| (3) any available survey; | ||
| (4) public hearings that involve health care | ||
| providers, researchers, injured patients, or the families of | ||
| injured patients speaking on COVID-19 or COVID-19 vaccine | ||
| experiences, including difficulties prescribing or filling | ||
| therapeutic prescriptions and difficulties encountered in | ||
| hospitals or with any medical boards; and | ||
| (5) any other relevant source, including the Vaccine | ||
| Adverse Event Reporting System maintained by the Centers for | ||
| Disease Control and Prevention and the Defense Medical Epidemiology | ||
| Database maintained for the United States Department of Defense. | ||
| SECTION 3. REPORT. Not later than January 1, 2024, the | ||
| department shall prepare and submit to the governor, lieutenant | ||
| governor, speaker of the house of representatives, and chairpersons | ||
| of legislative standing committees with jurisdiction over health | ||
| and safety a written report summarizing the information compiled in | ||
| the study and any recommendations for legislative or other action | ||
| to reduce the prevalence of COVID-19 vaccine side effects. The | ||
| department may make the report available to the public and post the | ||
| report on the department's Internet website. | ||
| SECTION 4. EXPIRATION. This Act expires September 1, 2025. | ||
| SECTION 5. EFFECTIVE DATE. This Act takes effect | ||
| immediately if it receives a vote of two-thirds of all the members | ||
| elected to each house, as provided by Section 39, Article III, Texas | ||
| Constitution. If this Act does not receive the vote necessary for | ||
| immediate effect, this Act takes effect September 1, 2023. | ||
